Adam B Weiner1, Richard S Matulewicz1, Jeffrey J Tosoian2, Joseph M Feinglass3, Edward M Schaeffer4. 1. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. 2. James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD. 3. Department of General Internal Medicine and Geriatrics, Northwestern University Feinberg School of Medicine, Chicago, IL. 4. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address: e-schaeffer@northwestern.edu.
Abstract
BACKGROUND: Understanding the characteristics of men who initially present with metastatic prostate cancer (mPCa) can better enable directed improvement initiatives. The objective of this study was to assess the relationship between socioeconomic status (SES) and newly diagnosed mPCa. MATERIALS METHODS: All men diagnosed with PCa in the National Cancer Data Base from 2004 to 2013 were identified. Characteristics of men presenting with and without metastatic disease were compared. A 4-level composite metric of SES was created using Census-based income and education data. Multivariable logistic regression was used to evaluate the association between SES, race/ethnicity, and insurance and the risk of presenting with mPCa at the time of diagnosis. RESULTS: Of 1,034,754 patients diagnosed with PCa, 4% had mPCa at initial presentation. Lower SES (first vs. fourth quartile; odds ratio [OR] = 1.39, 95% CI: 1.35-1.44), black and Hispanic race/ethnicity (vs. white; OR = 1.47, 95% CI: 1.43-1.51 and OR = 1.22, 95% CI: 1.17-1.28, respectively), and having Medicaid or no insurance (vs. Medicare or private; OR = 3.91, 95% CI: 3.78-4.05) were each independently associated with higher odds of presenting with mPCa after adjusting for all other covariates. CONCLUSIONS: Lower SES, race/ethnicity, and having Medicaid or no insurance were each independently associated with higher odds of presenting with metastases at the time of PCa diagnosis. Our findings may partially explain current PCa outcomes disparities and inform future efforts to reduce disparities.
BACKGROUND: Understanding the characteristics of men who initially present with metastatic prostate cancer (mPCa) can better enable directed improvement initiatives. The objective of this study was to assess the relationship between socioeconomic status (SES) and newly diagnosed mPCa. MATERIALS METHODS: All men diagnosed with PCa in the National Cancer Data Base from 2004 to 2013 were identified. Characteristics of men presenting with and without metastatic disease were compared. A 4-level composite metric of SES was created using Census-based income and education data. Multivariable logistic regression was used to evaluate the association between SES, race/ethnicity, and insurance and the risk of presenting with mPCa at the time of diagnosis. RESULTS: Of 1,034,754 patients diagnosed with PCa, 4% had mPCa at initial presentation. Lower SES (first vs. fourth quartile; odds ratio [OR] = 1.39, 95% CI: 1.35-1.44), black and Hispanic race/ethnicity (vs. white; OR = 1.47, 95% CI: 1.43-1.51 and OR = 1.22, 95% CI: 1.17-1.28, respectively), and having Medicaid or no insurance (vs. Medicare or private; OR = 3.91, 95% CI: 3.78-4.05) were each independently associated with higher odds of presenting with mPCa after adjusting for all other covariates. CONCLUSIONS: Lower SES, race/ethnicity, and having Medicaid or no insurance were each independently associated with higher odds of presenting with metastases at the time of PCa diagnosis. Our findings may partially explain current PCa outcomes disparities and inform future efforts to reduce disparities.
Authors: Farzana A Faisal; Debasish Sundi; John L Cooper; Elizabeth B Humphreys; Alan W Partin; Misop Han; Ashley E Ross; Edward M Schaeffer Journal: Urology Date: 2014-12 Impact factor: 2.649
Authors: David C Miller; Mark S Litwin; Jonathan Bergman; Sevan Stepanian; Sarah E Connor; Lorna Kwan; William J Aronson Journal: J Urol Date: 2008-12-18 Impact factor: 7.450
Authors: Mark E Bensink; Scott D Ramsey; Tracy Battaglia; Kevin Fiscella; Thelma C Hurd; June M McKoy; Steven R Patierno; Peter C Raich; Eric E Seiber; Victoria Warren-Mears; Elizabeth Whitley; Electra D Paskett; S Mandelblatt Journal: Cancer Date: 2013-10-25 Impact factor: 6.860
Authors: Farzana A Faisal; Debasish Sundi; Jeffrey J Tosoian; Voleak Choeurng; Mohammed Alshalalfa; Ashley E Ross; Eric Klein; Robert Den; Adam Dicker; Nicholas Erho; Elai Davicioni; Tamara L Lotan; Edward M Schaeffer Journal: Eur Urol Date: 2015-10-09 Impact factor: 20.096
Authors: Ryan A Dornbier; Eric J Kirshenbaum; Marc H Nelson; Robert H Blackwell; Gopal N Gupta; Ahmer V Farooq; Christopher M Gonzalez Journal: World J Urol Date: 2019-02-27 Impact factor: 4.226
Authors: Neel H Patel; Jonathan Bloom; Joel Hillelsohn; Sean Fullerton; Denton Allman; Gerald Matthews; Majid Eshghi; John L Phillips Journal: Health Equity Date: 2018-05-01
Authors: Phum Tachachartvanich; Sylvia S Sanchez; Scarlett L Gomez; Esther M John; Martyn T Smith; Laura Fejerman Journal: PLoS One Date: 2020-06-01 Impact factor: 3.240
Authors: Sarah P Huepenbecker; Charlotte C Sun; Shuangshuang Fu; Hui Zhao; Kristin Primm; Sharon H Giordano; Larissa A Meyer Journal: Cancer Date: 2021-08-04 Impact factor: 6.860